Overview

Interleukin-2 on Refractory Dermatomyositis

Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.
Phase:
Phase 3
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Aldesleukin
Interleukin-2